Trial Profile
Phase 1-2, Randomised, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intraputamenal Cerebral Dopamine Neurotrophic Factor (CDNF) Infusions Via an Investigational Drug Delivery System to Patients With Parkinson's Disease
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs HER-096 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Herantis Pharma
- 16 Sep 2020 Topline results assessing safey and toleratibility of CDNF infusions, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 Results presented at the 24th International Congress of Parkinson's Disease and Movement Disorders
- 16 Sep 2020 Results assessing exploratory fluid-based biomarker endpoints of the 12-month treatment period, presented at the 24th International Congress of Parkinson's Disease and Movement Disorders